In RPMI with serum, the screen identified rifabutin (RBT) as being 133-fold more potent than rifampin (RIF) against , with MICs of 0.031 渭g/ml and 4 渭g/ml respectively. No difference in RBT vs. RIF activity was observed when MHII was used as the culture media. RBT possesses ...
Rifamycins, including rifampin (RIF), rifapentine (RFP), and rifabutin (RFB), are the cornerstones of TB therapy due to their potent bactericidal activity and their ability to inhibit DNA‐dependent RNA synthesis in prokaryotes25. RFB is a hydrophobic drug (LogP = 4.7) with reduced potenti...
Rifabutin is a spiro-piperidyl-rifamycin derived from rifamycin-S. It is structurally related to rifampin and shares many of its properties. Rifabutin has ... CM Kunin - 《Clinical Infectious Diseases》 被引量: 300发表: 1996年 Rifabutin Synopsis Rifabutin is a derivative of rifamycin S with ac...
Rifampin [*analogs & derivatives, *therapeutic use]Tuberculosis, Pulmonary [*prevention & control]Background Preventing active tuberculosis (TB) from developing in people with latent tuberculosis infection (LTBI) is important for global TB control. Isoniazid (INH) for six to nine months has 60% to...
Patients who discontinued immunosuppressants before TB diagnosis and those with rifampin-resistant TB were excluded. The SOTR group was matched with a 1:3 ratio to the non-SOTRs who were treated with rifampin-based regimens. The primary outcome was survival treatment completion without early ...
A Comparison of Two Regimens for the Treatment of Mycobacterium avium Complex Bacteremia in AIDS: Rifabutin, Ethambutol, and Clarithromycin versus Rifampin, Ethambutol, Clofazimine, and Ciprofloxacin. Background: Bacteremia with the Mycobacterium avium complex is common in patients with the acquired immun...
A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifa- butin, ethambutol, and clarithromycin versus rifampin, ethambutol, clo- fazimine, and ciprofloxacin. N Engl J Med 1996; 335:377-83.
Rifampin and Rifabutin Resistance Mechanism in Helicobacter pylori. Antimicrob. Agents Chemother. 1999, 43, 1497–1499. [Google Scholar] [CrossRef] [PubMed] [Green Version] Fiorini, G.; Zullo, A.; Vakil, N.; Saracino, I.M.; Ricci, C.; Castelli, V.; Gatta, L.; Vaira, D. ...